What is the story about?
What's Happening?
Annovis Bio, Inc. has published a peer-reviewed article in Biomolecules detailing the pharmacokinetic profile of a new crystal form of buntanetap. The study compares the new dihydrate crystal form to the original anhydrous form, highlighting its stability and preservation of therapeutic efficacy. The new form is currently used in a Phase 3 clinical trial for early Alzheimer's disease, with key readouts expected in Fall 2026 and 2027. The publication reinforces the consistency and reliability of Annovis' lead asset.
Why It's Important?
The publication of the pharmacokinetic profile of the new crystal form of buntanetap is significant for Annovis Bio's ongoing clinical trials and intellectual property protection. By demonstrating the stability and efficacy of the new form, Annovis strengthens its position in developing therapies for neurodegenerative diseases. The extended intellectual property protection into the 2040s enhances the company's competitive edge, potentially leading to improved patient outcomes and business growth.
AI Generated Content
Do you find this article useful?
